Navidea Biopharmaceuticals, Inc. Common Stock (NY:NAVB)

N/A UNCHANGED

Last Price Updated: 8:00 PM EDT, Oct 5, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Navidea Biopharmaceuticals, Inc. Common Stock

< Previous 1 2 3 Next >

Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations

January 26, 2024

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

December 01, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock

October 05, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel

August 10, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

July 31, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

July 28, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

July 27, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down

July 13, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets

June 30, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock

June 16, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment

June 16, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

June 07, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice

June 02, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down

June 01, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market

May 22, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

May 11, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications

May 08, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit

April 27, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694

April 13, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down

March 30, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results

March 21, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update

March 15, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline

January 03, 2023

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Files Appeal in CRG Case

November 30, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

November 28, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

November 14, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

November 07, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update

November 04, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

October 05, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

September 30, 2022

From Navidea Biopharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.